Semaglutide for Low Back Pain

Low back pain is the leading cause of disability in the United States, and obesity is a major risk factor for its development. GLP-1 receptor agonists such as Semaglutide have emerged as effective weight loss agents that may also reduce chronic pain through weight reduction and other mechanisms. This randomized, double-blind, placebo-controlled trial will enroll 250 adults with chronic low back pain and obesity, randomized 1:1 to weekly Semaglutide 2.4 mg or placebo for 52 weeks. The primary outcome is change in low back pain severity, with secondary outcomes including pain-related disability and quality of life.

NCT Number	NCT07731256
Lead Sponsor	Washington University School of Medicine Collaborators: Novo Nordisk A/S
Conditions	Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Enrollment	250 participants
Start Date	2027-02-01
Primary Completion	2031-01-01 (estimated)
Study Completion	2031-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-28